Losartan and aki
Pro Research Analysisby 
Searched over 200M research papers
Losartan and Acute Kidney Injury (AKI): A Comprehensive Review
Introduction to Losartan and AKI
Losartan, an angiotensin II receptor antagonist, is widely used to manage hypertension and protect kidney function. However, its role in acute kidney injury (AKI) and subsequent chronic kidney disease (CKD) has been a subject of extensive research. This article synthesizes findings from multiple studies to provide a clear understanding of losartan's impact on AKI and its progression to CKD.
Dual Renin-Angiotensin System Blockade and AKI Risk
Increased AKI Incidence with Combination Therapy
Research indicates that dual blockade of the renin-angiotensin system (RAS) using losartan and lisinopril significantly increases the incidence of AKI compared to monotherapy with losartan alone. In a study involving veterans with type 2 diabetes, the incidence of AKI was 12.2 per 100 patient-years in the combination therapy group versus 6.7 per 100 patient-years in the monotherapy group . This suggests that while dual RAS blockade may offer some therapeutic benefits, it also poses a higher risk for AKI.
Outcomes of AKI in Monotherapy vs. Combination Therapy
Interestingly, patients who developed AKI under monotherapy had lower rates of kidney function recovery and higher mortality compared to those on combination therapy. Specifically, the recovery rate of kidney function was 66.3% in the monotherapy group versus 75.9% in the combination therapy group, and the 30-day mortality was significantly higher in the monotherapy group (15.0% vs. 4.7%) . This highlights the complex balance between therapeutic efficacy and adverse outcomes in RAS blockade strategies.
Losartan's Protective Role Post-AKI
Reduction in CKD Progression and Mortality
Losartan has been shown to mitigate the progression of CKD and reduce mortality following AKI. In a murine model, losartan administration post-AKI significantly reduced mortality, blood pressure, albuminuria, azotemia, and kidney fibrosis compared to untreated controls . These findings underscore losartan's potential in improving long-term kidney outcomes after an AKI episode.
Gene Expression and Anti-AKI Effects
Further studies have explored the molecular mechanisms underlying losartan's protective effects. In a rat model of ischemic AKI, losartan treatment altered the expression of numerous genes involved in inflammation and apoptosis, such as monocyte chemoattractant protein-1 (CCL2) and suppressor of cytokine signaling 3 (SOCS3) . These genetic changes contribute to losartan's ability to inhibit kidney damage and promote recovery.
Cognitive and Synaptic Protection
Impact on Cognitive Function and Synaptic Plasticity
AKI can also lead to cognitive impairments due to increased oxidative stress and inflammation in the brain. Losartan has been found to protect against these cognitive deficits by modulating oxidative stress in the hippocampus. In a study, losartan treatment improved spatial memory and synaptic plasticity in AKI-induced cognitive impairment models . This suggests that losartan's benefits extend beyond renal protection to include neurocognitive health.
Comparative Efficacy with Other RAAS Inhibitors
Losartan vs. Captopril
Comparative studies between losartan and captopril, another RAAS inhibitor, have shown that both drugs effectively attenuate drug-induced AKI. However, losartan was found to be superior in improving glomerular filtration rate (GFR), while captopril was more effective in normalizing certain biomarkers like ICAM-1 and KIM-1 Zafar2018Amin2017. This indicates that while both drugs are beneficial, their effects may vary depending on the specific parameters of kidney injury.
Conclusion
Losartan plays a significant role in managing AKI and preventing its progression to CKD. While dual RAS blockade increases the risk of AKI, losartan alone offers substantial protective benefits post-AKI, including reduced CKD progression, improved kidney function recovery, and enhanced cognitive outcomes. Comparative studies with other RAAS inhibitors like captopril further highlight losartan's unique advantages in certain aspects of kidney protection. These findings support the continued use and investigation of losartan in AKI management and recovery strategies.
Sources and full results
Most relevant research papers on this topic